acid (EET) was reported both to dilate and to constrict pulmonary blood vessels. We propose that these seemingly contradictory results could be explained by differences in responses to 5,6-EET in large-conductance pulmonary arteries (PA) compared with smaller PA and resistance vessels. Thus we found that in rings of extralobar PA [Ͼ2-mm outside diameter (OD)], in which active tension had been increased with PGF 2␣, 5,6-EET produced relaxation in a concentration-and cyclooxygenase (COX)-dependent manner. In contrast, 5,6-EET increased tension in intralobar (1-to 2-mm OD) PA. Small extralobar PA (2-to 2.5-mm OD) exhibited intermediate responses. In the intact lung, the net effect of 5,6-EET (1 ϫ 10 Ϫ8 -1 ϫ 10 Ϫ5 M) was an increase in pulmonary vascular resistance (PVR) from 13.0 Ϯ 0.5 to 47.8 Ϯ 4.6 mmHg ⅐ 100 ml Ϫ1 ⅐ min Ϫ1 (EC50 5.9 Ϯ 1.7 ϫ 10 Ϫ7 M). The increase in PVR was accompanied by a 10-fold increase in perfusate thromboxane (TX)B2 concentration. The 5,6-EETinduced increase in PVR was prevented with indomethacin (100 M), a cyclooxygenase inhibitor, or ONO-3708 (20 M), a TX/PGH2 (TP) receptor antagonist, but not with OKY-046 (700 M), a TX synthase inhibitor. These results demonstrate that although 5,6-EET dilates large extralobar PA segments in a COX-dependent manner, in the intact rabbit lung 5,6-EET produces constriction that requires synthesis of a COX-dependent agonist of the TP receptor other than TX.
cytochrome P-450; pulmonary vascular resistance; arachidonic acid; prostaglandin; endoperoxide; 5,6-epoxy-eicosatrienoic acid BOTH CYCLOOXYGENASE (COX)-and lipoxygenase-mediated products of arachidonic acid (AA) metabolism have been established as important participants in the regulation of pulmonary vascular tone (13, 29) . In contrast, the role of products of the third pathway of AA metabolism, i.e., the cytochrome P-450 monooxygenase pathway, are less well characterized (12) . Pulmonary AA metabolism via cytochrome P-450 monooxygenase activity to the four regioisomeric (5,6-; 8,9-; 11,12-; and 14,15-) cis-epoxyeicosatrienoic acids (EETs) has been observed in dogs, rabbits, guinea pigs, rats, and humans (3, 14, 15, 26, (32) (33) (34) (35) . We previously reported (25, 26) that in isolated canine pulmonary vascular rings contracted with either PGF 2a or U-46619, a thromboxane (TX)/PGH 2 (TP) receptor agonist, administration of 5,6-EET decreased active tension in a concentration-dependent manner. Similarly, in isolated, perfused canine lungs in which the pulmonary vascular resistance (PVR) was increased with serotonin or U-46619, 5,6-EET decreased PVR. Collectively, these results suggested a vasodilator action for 5,6-EET in the pulmonary circulation of the dog (25) .
Of the EETs synthesized in the rabbit lung, the most abundant regioisomer formed was reported to be 5,6-EET (34) . Similar to our observations in isolated pulmonary vascular rings from the dog (25, 26) , Schwartzman et al. (22) reported that 5,6-EET elicited a concentration-dependent decrease in active tension in rabbit pulmonary artery (PA) rings. In contrast to reports that suggested that 5,6-EET was a pulmonary vasodilator, Zhu et al. (35) found that 5,6-EET, as well as the other EET regioisomers, constricted isolated rabbit PA. A possible explanation of these contradictory results might reside in the fact that Schwartzman et al. (22) studied effects of 5,6-EET on active tension in rings of large conduit pulmonary vessels, whereas Zhu et al. (35) described 5,6-EET-evoked constriction in smaller cannulated and pressurized PA. Thus the seemingly opposite responses obtained for 5,6-EET in the rabbit pulmonary vasculature in these two reports may be a consequence of differences in the size of the pulmonary vessels studied or the location from which they were obtained; for example, Park et al. (18) observed that large extralobar rabbit PA contracted to epinephrine whereas intralobar PA of the same diameter did not. However, both large extralobar and intralobar PA of the same diameter constricted to serotonin, whereas smaller intrapulmonary arteries did not (18) .
In the present study, we propose that the effect of 5,6-EET on large extralobar PA segments in the rabbit is to decrease active tension via COX-dependent synthesis of a pulmonary vasodilator such as PGI 2 , in a manner similar to that which we observed in the dog (25) . Moreover, we propose that in smaller intralobar PA segments and resistance vessels, 5,6-EET increases active tension through activation of the TP receptor, resulting from increased synthesis of TX or a related COX-dependent endoperoxide. To test these hypotheses, we compared effects of 5,6-EET on active tension in extralobar, large (Ͼ2 mm)-outside diameter (OD) isolated rabbit PA rings with those observed in smaller (1-to 2-mm OD) extralobar and intralobar rings. To investigate the overall effect of 5,6-EET on the pulmonary resistance vessels, we measured 5,6-EET-mediated changes in PVR in isolated, perfused rabbit lungs (1, 5, 7) . We examined whether the effects of 5,6-EET on vascular reactivity were dependent on COX activity, TX synthesis, or TP receptor activation.
METHODS
Animal preparation. Adult New Zealand White rabbits (2.4-3.0 kg) were anesthetized with pentobarbital sodium (15 mg/kg iv) 10 min after intramuscular administration of ketamine (8 mg/kg) and xylazine (2 mg/kg). A tracheostomy was performed for insertion of a tracheal cannula. The animals were ventilated via a fixed volume ventilator (Harvard) with room air (8-10 ml/kg tidal volume, 15 cycles/min). A catheter was inserted into a carotid artery for administration of heparin (1,000 units iv) 10 min before exsanguination of the animal. The protocol for animal use was approved by the Saint Louis University Institutional Animal Care and Use Committee.
Isolated vessel protocols. After exsanguination of the rabbit, extralobar and intralobar PA were dissected free of extravascular tissue and stored in cold (4°C) physiological salt solution (PSS) containing (in mM) 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, 0.026 Na-EDTA, and 11.1 glucose (pH 7.4) saturated with 95% O2-5% CO2 as previously described for isolated canine vessels (25) . Immediately before use, the pulmonary vessels were cut into rings 3-4 mm in length and suspended in water-jacketed tissue chambers containing 10 ml of PSS gassed with 95% O 2-5% CO2 at 37°C. Each ring was mounted between two stainless steel support wires (smaller-gauge wires were used for the smallest vessels). Ring tension was measured from one of the support wires attached to an isometric force transducer (FT03, Grass) and was recorded continuously on a polygraph (model 7, Grass). To maximize length-tension relationships in the vascular ring preparations, each ring was placed under a basal tension determined to result in a maximal contractile response to KCl (60 mM). After an initial depolarizing contraction with KCl (60 mM), the rings were washed with PSS and allowed to return to basal tension over a period of 30 min. At basal tension, concentrations of 5,6-EET (1 ϫ 10 Ϫ8 -1 ϫ 10 Ϫ5 M, each in 1 l of absolute ethanol) were added individually or cumulatively to the rings. In different but identically prepared ring preparations, 5,6-EET was administered to PGF 2␣-contracted rings after incubation for 30 min with vehicle or indomethacin, a COX inhibitor (30 M), a concentration shown previously to inhibit EET-stimulated eicosanoid synthesis (25) . At the concentrations used, the ethanol vehicle did not alter the basal tension or active tension of these PA rings. PGF 2␣ (1-5 ϫ 10 Ϫ6 M) was added to achieve a contraction that was 50-80% of that produced with KCl (60 mM). After administration of 5,6-EET, vessels were washed with PSS and recontracted with PGF 2␣ and acetylcholine (1 ϫ 10 Ϫ6 M) was administered. Vessels in which acetylcholine did not decrease active tension Ͼ60% were considered to lack functional endothelium and were not used in the data analysis. To confirm that the effects of indomethacin on 5,6-EET-induced changes in active tension were due to COX inhibition, in a separate group of rings, 5,6-EET was added to PGF 2␣-contracted rings in which COX activity was inhibited for 30 min with meclofenamate (100 M).
Enzyme immunoassay. Enzyme immunoassay (EIA) was performed for quantitative identification of 6-keto-PGF 1␣ (the stable degradation product of PGI2) and TXB2 (the stable degradation product of TXA 2) as described previously (20, 25) . Briefly, enzymatic tracers consisted of 6-keto-PGF 1␣ or TXB 2 covalently linked to purified acetylcholinesterase as described previously (20) . The sample (50 l) was combined with 50 l of enzymatic tracer in a well of a 96-well microtiter plate (Nunc) that had been precoated with 2 g/well goat anti-rabbit IgG antibody (Calbiochem). The antiserum for 6-keto-PGF 1␣ or TXB2 (Cayman) was then added (50 l). The plates were incubated for 18-20 h at room temperature and washed three times with 500 g of potassium phosphate buffer (1 ϫ 10 Ϫ2 M, pH 7.4; containing 0.05% Tween 20). After washing, 200 l of Ellman's reagent was added to each well. Ellman's reagent consisted of 2 g/ml acetylthiocholine iodide and 2.15 g/ml 5,5Ј-dithiobis(2-nitrobenzoic acid) (DTNB) in 1 ϫ 10 Ϫ2 M potassium phosphate buffer. The reaction product (reduced DTNB) was monitored at 405 nm in a BIO-TEK (model EL-309) EIA plate reader. All samples and standards were run in duplicate. Sample unknowns were determined by comparison to standards with log-logit data transformation.
Isolated lungs. Rabbit lungs were isolated as described previously (23) . Briefly, a midsternal thoracotomy was performed, and the heart and lungs were removed en bloc. Fluid-filled catheters were placed into the PA and the left atrium for lung perfusion and pressure measurements. The isolated lungs were ventilated at 10 ml/kg with 26-30 breaths/min of 15% O2-6% CO2-79% N2 to achieve a perfusate pH of 7.33 Ϯ 0.01, PCO2 of 38.1 Ϯ 2.8 mmHg, and PO2 of 107.3 Ϯ 5.9 mmHg. The lungs were perfused in a humidified chamber (34-37°C) in a recirculating manner with 150 ml of PSS containing (in mM) 118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, 0.026 Na-EDTA, and 11.1 glucose (pH 7.4) to which 5% dextran (mol wt 70,000) was added for maintenance of oncotic pressure. Pulmonary arterial (Ppa, inflow), pulmonary venous (Pla, outflow), and airway pressures were recorded continuously. Microvascular pressure (Pmv) was measured by the double occlusion method (6, 31) . To prevent atelectasis, positive end-expiratory airway pressure (1-1.5 mmHg) was maintained throughout each experiment. Lungs were perfused under zone III conditions (Ppa Ͼ Pla Ͼ airway pressure) with a roller pump (Masterflex, Cole Parmer Instrument) at 100 ml/min. Outflow pressure was adjusted to 2-3 mmHg via a screw clamp on the outflow tubing. In those experiments in which antagonism of the TX receptor was required, ONO-3708, the TX receptor antagonist (ONO Pharmaceutical), was added to the perfusate reservoir 15 min before measurements of vascular pressures were obtained. Total PVR was calculated as (Ppa Ϫ Pla)/ perfusate flow rate. Arterial PVR was calculated as (Ppa Ϫ Pmv)/perfusate flow rate, and venous PVR was calculated as (Pmv Ϫ Pla)/perfusate flow rate (25) . In a separate group of experiments, lungs were perfused with autologous blood. In each group, 5,6-EET was added to the perfusate (in ethanol). The final ethanol concentration in the perfusate was Ͻ0.01%, a concentration that did not change PVR.
In PSS-perfused lungs, perfusate samples were taken for measurement of TXB2 and 6-keto-PGF1␣. After each pressure measurement period 6-keto-PGF1␣ and TXB2 were measured by enzyme-linked immunoassay. COX activity was inhibited with indomethacin (100 M) (25) . TX synthase activity was inhibited with OKY-046 (7 ϫ 10 Ϫ4 M, ONO Pharmaceuticals; Ref. 31 ). The TP receptor was antagonized with ONO-3708 (2 ϫ 10 Ϫ6 , 2 ϫ 10 Ϫ5 , and 2 ϫ 10 Ϫ4 M). Fifteen minutes after pharmacological inhibitors were added to the perfusate, samples were obtained for measurement of TXB 2 and 6-keto-PGF1␣. Within 5 min after the administration of 5,6-EET (10 M) to the perfusate, pressures were recorded and an additional sample was obtained for measurement of TXB 2 and 6-keto-PGF1␣. In experiments using ONO-3708, a TP receptor antagonist, U-46619 (0.1-10 g), a stable TP receptor agonist, was administered to verify receptor inhibition (31) .
Statistical methods. All values are expressed as means Ϯ SE. Differences between experimental groups were determined by ANOVA. If the F ratio indicated significant differences, a Tukey's protected t-test was used to establish differences between individual sample means. When appropriate, a Student's t-test for paired data was used. Values of P Ͻ 0.05 were considered to be statistically significant.
RESULTS

Effect of 5,6-EET on active tension in PGF 2␣
-contracted PA rings. The dominant response of 5,6-EET administered to PGF 2␣ -contracted isolated rings of large main (5.6 Ϯ 0.3-mm OD) and extralobar branch (2.1 Ϯ 0.1-mm OD) PA was a sustained concentrationdependent decrease in active tension (maximum relaxation occurred at ϳ3 min; Fig. 1 ). Before the relaxation a small contraction of short duration (within the 1st minute after 5,6-EET administration) was observed (Fig. 2) . Both the 5,6-EET-induced relaxation and contraction responses were inhibited by indomethacin (Fig. 3) . However, only the contraction response to 5,6-EET was inhibited by ONO-3708 (2 ϫ 10 Ϫ5 M), a selective TP receptor antagonist, suggesting that this response was dependent on the synthesis of TX or another COX-dependent TP receptor agonist. In these rings, acetylcholine (1 ϫ 10 Ϫ6 M) resulted in a decrease in active tension of 78.4 Ϯ 4.4% in vehicle-treated rings and 73.6 Ϯ 2.64% in indomethacin-treated rings (n ϭ 5; not significant). The lack of effect of indomethacin on acetylcholine-induced relaxation indicated that the vessels contained functional endothelium and remained capable of relaxing. Identical vessel studies were performed with a chemically dissimilar inhibitor of COX activity, meclofenamate. Results of these studies were consistent with those obtained with indomethacin. Meclofenamate (100 M) reduced the 5,6-EETinduced decrease in active tension from 65.2 Ϯ 5.9% to 2.8 Ϯ 1.7% at 10 M 5,6-EET (n ϭ 5; P Ͻ 0.01), confirming that a chemically dissimilar inhibitor of COX activity produced an identical effect. Effects of 5,6-EET on relaxation of PGF 2␣ -contracted extralobar branch PA rings were similar to main PA, with significant but small differences occurring only at the highest concentrations of 5,6-EET administered (Fig. 1) . However, compared with either main or extralobar branches, the concentration-response curve of intralobar PA rings (1.3 Ϯ 0.1-mm OD) was shifted to the right. These results demonstrate the greater potency of 5,6-EET for decreasing active tension in rings of main and extralobar PA branches of dissimilar diameter than in intralobar PA with diameters similar to, although slightly smaller than, those of extralobar branches.
Effect of 5,6-EET on active tension in PA rings at basal tension. At basal tension, 5,6-EET increased active tension in intralobar PA rings in a concentrationdependent manner (Fig. 4) . The concentration-response curve for 5,6-EET-induced increases in active tension in extralobar branches was shifted to the right of that for intralobar PA, demonstrating a lower sensitivity of extralobar branches to the contractile effect of 5,6-EET. Rings of main PA did not contract to 5,6-EET administered at basal tension.
Effect of 5,6-EET on PVR in isolated rabbit lungs. In lungs perfused with PSS, administration of 5,6-EET into the perfusate at concentrations of 1 ϫ 10 Ϫ9 to 1 ϫ 10 Ϫ5 M resulted in concentration-dependent increases in PVR (Fig. 5) . The EC 50 for this response was 5.9 Ϯ 1.7 ϫ 10 Ϫ7 M. Administration of a single bolus of 5,6-EET (1 ϫ 10 Ϫ5 M) was associated with an increase in total PVR resulting predominantly from the increase in PVR within the arterial segment (Fig. 6) . To determine whether a dilator component of 5,6-EET would be unmasked in the presence of increased PVR in the intact lung, U-46619 was infused before 5,6-EET administration. When P pa was raised from 13.4 Ϯ 2.9 to 27.3 Ϯ 6.1 mmHg with U-46619, administration of 5,6-EET resulted in a pressor response similar to that Ϫ8 -1 ϫ 10 Ϫ5 M) in isolated rabbit pulmonary arterial (PA) rings from main PA (n ϭ 5), extralobar branch PA (n ϭ 9), and intralobar PA (n ϭ 8). 5,6-EET was administered to vessels contracted with PGF2␣ (1 ϫ 10 Ϫ6 -5 ϫ 10 Ϫ6 M) to achieve 50-80% of the maximal contractile response to KCl (60 mM). *P Ͻ 0.05 compared with main PA; †P Ͻ 0.05 compared with extralobar branch PA. o.d., Outside diameter. observed in the absence of U-46619. A depressor response following the pressor response, similar to that seen in large isolated PA rings (Fig. 2) , was not observed in the intact lung preparation (data not shown). In lungs perfused with autologous blood, 5,6-EET (10 M) increased PVR 4.6 Ϯ 0.5-fold over PVR measured immediately before administration of 5,6-EET (Fig. 7) . These results demonstrate that, when administered in blood, 5,6-EET is not so avidly bound to plasma proteins or taken up by cellular elements in the blood that responses to it are prevented.
Effect of 5,6-EET on TXA 2 and PGI 2 synthesis in PSS-perfused rabbit lungs. In PSS-perfused lungs, samples of perfusate collected immediately after the completion of each pressure measurement were analyzed for concentrations of 6-keto-PGF 1␣ and TXB 2 , the stable degradation products of PGI 2 and TXA 2 , respectively. In the absence of pharmacological inhibitors, administration of 5,6-EET (1 ϫ 10 Ϫ5 M) increased concentrations of TXB 2 and 6-keto-PGF 1␣ in the lung perfusate (n ϭ 4; Fig. 8 ). The concentration of TXB 2 increased from 9.9 Ϯ 0.7 to 100.2 Ϯ 13.4 pg/ml perfusate, a 10-fold increase from basal, whereas 6-keto-PGF 1␣ increased from 100.3 Ϯ 8.3 to 206.4 Ϯ 24.6 pg/ml, a 2-fold increase from basal.
Effect of ONO-3708, a TP receptor antagonist, on 5,6-EET-induced changes in PVR.
In PSS-perfused rabbit lungs, ONO-3708 attenuated the 5,6-EET-induced increases in PVR in a concentration-dependent manner (Fig. 9) . At 200 M, ONO-3708 completely prevented the 5,6-EET-induced increase in PVR. It was also at this concentration of ONO-3708 that the pulmonary vasculature no longer responded to a 10-g bolus injection of U-46619, the TP receptor agonist (Fig. 9, inset) , suggesting that TXA 2 , or an endoperoxide-like TP receptor agonist, may mediate the 5,6-EETinduced increase in PVR.
Effect of OKY-046 and indomethacin on 5,6-EETinduced changes in PVR in lungs perfused with PSS.
Administration of OKY-046 (7 ϫ 10 Ϫ4 M) into the perfusate 30 min before administration of 5,6-EET (1 ϫ 10 Ϫ5 M) reduced the 5,6-EET-induced increase in TXB 2 by more than sixfold (n ϭ 4; Fig. 10 ) from 113.7 Ϯ 8.1 to 17.7 Ϯ 1.8 pg/ml perfusate, nearly to control levels. However, the OKY-046-mediated decrease in TX did not prevent the 5,6-EET-induced increase in PVR (Fig.  11) . OKY-046 only reduced the 5,6-EET-mediated increase in PVR by 12.75 Ϯ 2.03%. In contrast, COX inhibition with indomethacin (100 M) prevented the 5,6-EET-mediated increase in TX synthesis (Fig. 10) as well as the increase in PVR (Fig. 11) .
DISCUSSION
In the present study, we report differential responses to 5,6-EET administration in main, extralobar branch, and intralobar segments of the rabbit PA. In rings of large (Ͼ2 mm) PA isolated from the main, common PA, and extralobar portions of the right and left main branches contracted with PGF 2␣ , administration of 5,6-EET resulted in a concentration-dependent decrease in active tension. Differences in the amount of relaxation exhibited by main PA and extralobar branches were small and limited to the highest concentrations of 5,6-EET administered. However, 5,6-EET was significantly less potent in relaxing intralobar PA than either extralobar segment. In contrast, 5,6-EET was more potent at increasing active tension in intralobar PA rings compared with extralobar PA branches. When administered at basal tension, 5,6-EET did not increase active tension in main PA at any concentration administered. The differential responses to 5,6-EET observed in these rings from main and intralobar rabbit PA mimic the differential response to hypoxia observed in large and small rabbit PA. Hypoxia was reported to decrease contraction in large isolated PA vessel segments (4, 7, 17) and to increase it in small PA (7, 16) . It has been suggested that this differential response may provide a compensatory mechanism for modulation of the pulmonary arterial blood pressure, i.e., as small PA segments contract in response to hypoxia, large segments relax (4). A similar vasodilator mechanism to 5,6-EET in the large PA segments of the rabbit may modulate the pressure response to constriction of the small resistance segments.
Attempts to describe the responses of vasoactive compounds in the pulmonary circulation have often been limited to an examination of their vasoactive effects on either large conduit vessels or small resistance vessels. When effects of a variety of vasoactive compounds have been compared in large and small rabbit PA vessels, significant differences have been reported (18) . Specifically, epinephrine and phenylephrine potently stimulate contraction of large extralobar and intralobar PA of similar size but produce little response in smaller intralobar PA, whereas histamine contracts large and small intralobar PA with little effect on extralobar PA (18) . In the present study, we found 5,6-EET to be a potent constrictor of intralobar rabbit PA. 5,6-EET was significantly less potent in extralobar PA branches than in intralobar PA. Because 5,6-EET did not constrict extralobar main PA when administered at basal tension, the relaxation to 5,6-EET in PGF 2␣ -contracted vessels would be unopposed by a 5,6-EET-mediated constrictor effect. Small extralobar branches with diameters more similar to intralobar than main PA relaxed when 5,6-EET was administered to PGF 2␣ -contracted PA rings but contracted when it was administered to PA rings at basal tension.
Consistent with the results presented in the present study, Zhu et al. (35) described EETs as vasoconstrictors in small pressurized rabbit PA (300-to 500-m OD). Their results support the dependence of vasoconstriction on either COX activity or activation of the TP receptor that we report in the present study. More recently, Yaghi et al. (32) described a similar vasoconstrictor action for EETs in small (200-400 m) intralobar arterial rings of rats. The rat and rabbit respond similarly to 5,6-EET, whereas dogs respond to 5,6-EET with decreased active tension in isolated vessels and decreased PVR in the isolated, perfused lung, suggesting only a vasodilator role for 5,6-EET (25) . Thus the response to 5,6-EET in the pulmonary circulation appears to differ among species. However, the dependence on COX activity for the vasodilator action of 5,6-EET in large rabbit PA is consistent with results reported previously for dog pulmonary vessels (25) and suggests that in both dog and rabbit the vasodilator effect of 5,6-EET depends on the synthesis of a COXdependent pulmonary vasodilator. Because 5,6-EET increases intracellular calcium in endothelium and smooth muscle cells, it may activate phospholipases, resulting in the release of AA for synthesis of endogenous pulmonary vasodilators such as PGI 2 (25) or 20-hydroxyeicosatetraenoic acid (20-HETE) (3) . In the present study, we report that in the pulmonary circulation, 5,6-EET increases the concentration of 6-keto-PGF 1␣ , the nonenzymatic breakdown product of PGI 2 , suggesting that PGI 2 could mediate the dilator response. However, the dilator activity of exogenously added 20-HETE was also reported to require COX activity (3), suggesting that 20-HETE is either metabolized to a pulmonary vasodilator prostanoid or stimulates the synthesis of an endogenous vasodilator prostaglandin such as PGI 2 (3). 5,6-EET itself can be metabolized by COX to vasodilator prostanoids (10) . Therefore, the vasodilator activity of 5,6-EET in the rabbit pulmonary vasculature may depend on synthesis of endogenous COX product, such as PGI 2 , or other COX-dependent signaling molecules.
In isolated, perfused rabbit lungs in which PVR was increased with U-46619, Tan et al. (28) reported previously that 5,6-EET resulted in dilation of the rabbit pulmonary vasculature. We attempted to reproduce those findings by administering 5,6-EET to rabbit lungs under conditions that appeared to be identical to those described by Tan et al. We did not, however, observe vasodilation with administration of 5,6-EET in the presence of increased PVR with U-46619. In our studies of isolated, perfused rabbit lungs in which PVR was increased with U-46619, administration of 5,6-EET resulted only in increased PVR. The discrepancy between our results and those of Tan et al. suggests that factors other than species, vessel location, or vessel size may determine whether the net effect of 5,6-EET on the pulmonary circulation is to increase or decrease PVR. These might include factors such as the level of vascular COX-2 expression (8) or vascular TX receptor density (19) .
The finding that 5,6-EET decreased active tension in large (Ͼ2 mm)-conduit PA rings, precontracted with PGF 2␣ , is supported by the findings of Schwartzman et al. (22) that EETs relaxed rabbit PA rings precontracted with phenylephrine. In the present study, the 5,6-EET-mediated decrease in active tension in these large PA rings was often accompanied by a small, transient increase in active tension that preceded the larger, sustained relaxation (Fig. 2) . Although inhibition of COX activity with indomethacin attenuated the 5,6-EET-mediated decrease in active tension and the transient increase in active tension, ONO-3708 inhibited only the transient increase in tension. Together, these results suggest that in the rabbit the vasoconstrictor response to 5,6-EET predominates in the smaller PA and resistance vessels, whereas in the larger-conduit pulmonary vessels the 5,6-EET-mediated vasoconstriction is replaced with a dilator response mediated by a COX-dependent product such as PGI 2 . The net effect of 5,6-EET on PVR when infused into the intact pulmonary circulation was an increase in PVR.
The activity of EETs in most vascular beds has been reported to result in vasodilation (10, 21) . However, even in some systemic vascular preparations studied, EETs produce vasoconstriction; for example 5,6-EET was reported to constrict the vasculature of the rat kidney (11, 27) . In the rat kidney, the vasoconstrictor effect of 5,6-EET was also decreased with an inhibitor of COX activity (11, 27) or antagonism of the TP receptor (11) . In the present study, 5,6-EET was observed to preferentially stimulate the synthesis of TX (10-fold) compared with PGI 2 (2-fold) in the isolated rabbit lung, whereas 5,6-EET preferentially stimulated the synthesis of PGI 2 in the perfusate of the dog lung (25) . This difference in the profile of COX products synthesized in the rabbit and dog pulmonary circulation in response to 5,6-EET stimulation led us to examine whether constriction resulting from administration of 5,6-EET in the rabbit may be mediated by TX. Although the 5,6-EET-stimulated increase in TX in lung perfusate was prevented with either indomethacin or OKY-046, inhibition of TX synthesis had only a small effect on the 5,6-EET-induced increase in PVR whereas COX inhibition prevented it. Therefore, it appears that not TX, but an endoperoxide metabolite of COX activity, is the primary mediator of the 5,6-EET-mediated vasoconstrictor effect in the rabbit pulmonary circulation. Alternately, as platelets have been reported to metabolize 5,6-EET via COX activity (2, 9) to an endoperoxide metabolite of 5,6-EET, a 5,6-EET-derived endoperoxide, rather than the endoperoxide PGH 2 , might medi-ate the vasoconstrictor response of 5,6-EET in the rabbit pulmonary circulation.
The pulmonary circulation, like the systemic circulation, is not longitudinally homogeneous. In its progression from the right heart to the pulmonary capillaries, the pulmonary vasculature narrows and divides, its composition changing from large elastic to small muscular resistance arteries (30) . Longitudinal variation in responses to hypoxia and other vasoactive agents is widely recognized, although the mechanistic basis for the differences often remains poorly defined. In the present study, we report that within the pulmonary vasculature of the rabbit, 5,6-EET can evoke either a vasoconstrictor or a vasodilator response, depending on the size of the pulmonary vessel or the location from which it was obtained. We have presented evidence supporting a TX-or COX-dependent endoperoxide mechanism for the 5,6-EET-induced constrictor response in the small arteries and resistance vessels and COX-dependent synthesis of a vasodilator prostaglandin, such as PGI 2 , in the larger extralobar vessels. These mechanisms may be responsible for the difference in response to 5,6-EET between large and small rabbit pulmonary vessels.
